UK: Prescient strengthens pricing and market access capabilities with Dolon
Prescient Healthcare Group, a UK-based product strategy consultancy to the global biopharmaceutical industry, has acquired London-based pricing and market access consultancy Dolon, strengthening its ability...
Belgium: Ceres Pharma acquires Kela’s human health division
Kela Pharma, the human health division of Kela, a Belgian family-owned pharmaceutical company, has been acquired by Ceres Pharma, a Belgian based pharmaceutical company...
The Netherlands: Azafaros secures €132m in oversubscribed Series B
Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, has completed an...
Austria: Alantra acts as financial advisor to Perrigo on divestment of Richard Bittner
Alantra, a global alternative asset management, investment banking, and credit portfolio advisory firm, acted as exclusive financial advisor to Perrigo Company on the divestment...
China: AstraZeneca to acquire Gracell Bio for up to US$1.2bn
Nasdaq-listed Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases,...
Healthcare’s inflation-linked health check
The economic and geopolitical landscape changed dramatically early in 2022 with all parts of the economy, including healthcare and life sciences, left to face...
Sweden: Biotage recommends shareholders accept KKR’s SEK11.607bn public takeover offer
RWK Bidco, a company owned by KKR, has made a cash offer of SEK145 per share for Nasdaq Stockholm-listed biotechnology company Biotage.
The board has...
InFocus: Verena Ahnert and Andre Valente, Partners at L.E.K. Consulting, analyse sustainability in the...
At the Glasgow Conference of Parties (COP26) in November 2021, governments and the private sector sought to put the global economy on the path...
UK government’s Investment Summit: what healthcare and life sciences investors want to see
This week’s UK Global Investment Summit is the first major indicator of the Starmer government’s approach to investment in key sectors including healthcare and...
Switzerland: Alentis Therapeutics raises US$181.4m to advance the clinical development of Anti-Claudin-1 ADCs in...
Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumours and organ fibrosis, has raised US$181.4m in Series D financing. The...
Advertisement
